8 presumption that the MDA products of the tumor spheroids present a balanced allele 169 amplification without losing one of the two alleles. 170 171
Low-depth WGS reveals the somatic CNAs and genetic subclones 172
First, we assessed the somatic CNAs of the primary ovarian cancer tissues and the 173 tumor spheroids from the ascites (Additional file 1: Table S1 ). We carried out low-depth 174 WGS using the Illumina platform to produce 8.53 ± 0.879 (× 10 6 ) sequenced reads for each 175 sample. As a result, we generated CNA profiles based on which we performed a hierarchical 176 clustering analysis (Fig. 3A) . The clustering yielded three distinct genetic subgroups. The 177 primary ovarian cancer tissues (RO 1-7 and LO, named "Primary clone" and colored red) 178
were clustered together. In contrast, the tumor spheroids from the ascites were divided into 179 two clusters, one of which showed a primary-like CNA profile (AC 1-3 and 7-8, named 180 "Ascites clone 1" and colored yellow), but the other presented a normal-like profile (AC 4-6 181 and 9-10, named "Ascites clone 2", colored green). 182
Interestingly, the CNA profiles showed that deletion of FAT1 and amplification of 183 MYC, PARP10, and CYC1 were shared by most of the samples (Fig. 3B ). These genes are 184 reported to be recurrently deleted (FAT1) or amplified (MYC, PARP10, and CYC1) in pan-185 cancer data [13] . These facts suggest that the shared CNAs might be the driving alterations at 186 the first stage of cancer initiation. However, the primary clone had exclusive focal 187 amplifications of KDM5A and NOTCH3 (Fig. 3B ), which are known as recurrently amplified 188 genes in ovarian cancer [13, 14] . These focal amplifications of KDM5A and NOTCH3 might 189 allow the primary clone to overwhelm the other subclones and finally dominate the left and 190 right ovaries. However, we did not find a critical focal amplification or a deep deletion 191 exclusive to Ascites clone 1. This implied that other types of alterations might drive Ascites 192 clone 1 to survive or propagate in the peritoneal fluid.
194

WES reveals somatic SNVs and genetic subclones 195
To identify the somatic SNVs, the samples underwent WES. For each sample, the 196 sequencing run generated 134 ± 21.4 depth of data, covering the whole exome of the human 197 genome. As a result, 171 somatic SNVs were identified by variant calling from all the 198 samples (Additional file 2: Table S2 ). The results shown in acquisition of anoikis resistance in various malignancies [15, 16] . Therefore, the mutation in 207 KRAS in the Ascites clone might provide an additional fitness gain for anchorage-208 independent survival in the ascites TME. However, both the Primary and Ascites clones 209 shared somatic SNVs in TP53 and ARID1A, which are well-known driver mutations in 210 ovarian cancer [17, 18] . At the initial stage of tumorigenesis, these mutated genes might be 211 tumor-initiating SNVs in conjunction with the CNAs of FAT1, MYC, PARP10, and CYC1. 212
In addition to these somatic variants, the patient had germline variants in BRCA1 213 (NM_007294.3:c.1511dupG) and TP53 (NM_001126118:c.C98G), which are well-known 214 susceptibility genes of ovarian cancer and are likely to predispose individuals to ovarian 215 cancer and promote carcinogenesis (Additional file 3: Table S3 ) [19, 20] . 216 217
Cellular composition of the tumor spheroids 218
Regarding the CNAs, Ascites clone 2 had no alteration except for amplification of the 219 8q24 region. Concerning the SNVs, Ascites clone 2 had fewer mutations than the other 220 clusters. Based on these facts, we examined the possibility that normal cells exist in a tumor 221 spheroid. We assumed that the VAF distribution of Ascites clones 1 and 2 would be similar if 222 the two subclones had a similar proportion of normal cells. However, the VAF of Ascites 223 clone 2 would be low if a single tumor spheroid from the clone included a high proportion of 224 normal cells. We tested this idea by plotting the VAF distribution of each sample (Fig. 5) . The 225 results showed that most of the VAF distributions from the Primary clone and Ascites clone 1 226 were located at a higher range than those from Ascites clone 2. Therefore, we concluded that 227 the small number of CNAs and SNVs in Ascites clone 2 was not due to their true 228 characteristics but because the proportion of tumor cells in the tumor spheroid was small. 229
Consequently, we excluded Ascites clone 2 from the following phylogenetic analysis. The phylogenetic trees were constructed from the CNA and SNV data. We achieved a 243
CNA-based phylogeny analysis by identifying the common chromosomal breakpoints, 244 calculating a trinary event matrix, and constructing a maximum parsimony tree [28] . The 245 phylogenetic tree showed that an ancestral cancer clone accumulated CNAs and divided into 246 two clones, which gained additional exclusive CNAs (Fig. 6A) . Notably, these two genetic 247 clones were composed of tumor spheroids from ascites and tumor tissues. Potentially, 248 physically separated and biologically distinct TMEs might drive cancer cells into different 249 alteration statuses. 250
Maximum parsimony tree generation using the CNA data has a couple of limitations. 251
First, this approach needs to set thresholds to define the amplified, neutral, and deleted status. 252
The resultant tree is significantly affected by thresholds, and there is no golden rule to set the 253 thresholds. Second, the proportion of normal cells in a sample has a substantial impact on a 254 tree because the CNA status might be incorrectly assigned according to the normal cell 255 portion. For example, the VAFs of RO6 (Fig. 5) show that the sample had a large number of 256 normal cells. In this case, the copy number value of RO6 was close to the normal value ( Fig.  257 3A), although the overall pattern was not similar to that of the normal sample. Thus, the 258 thresholding led RO6 to be the same as the normal sample. For this reason, we excluded RO6 259 when constructing the maximum parsimony tree based on the CNA data. 260
Next, we constructed a phylogenetic tree from the SNV data. This approach does not 261 use manual thresholding, and a phylogenetic tree is less affected by a normal cell portion. 262 Therefore, we expected that, compared with the CNA-based approach, this approach would 263 provide a more accurate result. The results showed that the cancer cells accumulated 264 mutations as a single clone and divided into two independent clones ( The dominant clones found in the right ovary were absent in the ascites TME, and we found 301 44 tumor spheroid-specific somatic SNVs (Additional file 2: Table S2 ). Furthermore, the 302 comparable allele frequencies between the common mutations and tumor spheroid-specific 303 mutations suggest that the tumor spheroids in the ascites TME are comprised of genetically 304 homogeneous tumor cells compared with the primary tissues. Therefore, we conclude that the 305 tumor spheroids were from a single subclonal lineage, supporting a mono-and early-seeding 306 origin of the tumor spheroids in this patient. Based on these perspectives, we drew a potential 307 evolutionary trajectory of the tumor from the patient (Fig. 7A) . The tumor was initiated at the 308 right ovary to generate the ancestral clone. With further accumulation of mutations, the 309 ancestral clone evolved into two subclones, the first of which was found in the right ovary 310 and metastasized to the left ovary. The second subclone shed into the ascites TME and 311 became extinct or dominated by the first subclone in the right ovary (Additional file 4: Table  312 S4). Eventually, the Ascites subclone moved to the peritoneal cavity. In addition, the 313 summary of genome-wide somatic CNAs and SNVs indicated that the tumor cells in the 314 primary tissue and the ascites possessed exclusive alterations as well as common ones (Fig.  315 7B). This result shows that the tumor cells in the primary tissue and the ascites were two 316 subclonal lineages, which branched from one ancestral lineage. 317 14 318
Discussion
319
In this study, we attempted to determine the presence of genetic heterogeneity within 320 and between a primary tumor and the associated tumor spheroids in the ascites by performing 321 multi-region sequencing of the primary tumor and genetic profiling of the individual tumor 322 spheroids using the laser-aided cell isolation technique. We performed both WGS and WES 323 of the primary tumor and tumor spheroid samples. First, we discovered high ITH levels in 324 eight primary tissues and ten tumor spheroids. We also discovered that the CNA profiles in 325 the primary and associated tumor spheroids were separated into two distinct genetic clusters, 326
suggesting that the TME may be operative during tumor evolution. Second, we identified 327 somatic SNVs using WES. We discovered a total of 171 somatic SNVs from all the samples, 328 and 66 (38.6 %) of these SNVs were ubiquitous mutations that were common to the primary 329 tumor and tumor spheroids. The rest were either primary-only (61 SNVs, 35.7 %) or ascites-330 only (44 SNVs, 25.7 %) mutations, highlighting the notion that the tumor spheroids might 331 have diverged early and accumulated additional mutations independently from the Primary 332 clone. Supporting this idea, both phylogenic analyses, using the CNAs and SNVs, showed 333 that the tumor spheroids might have diverged early from an ancestral tumor clone, evolved 334 further with distinctive genomic profiles, and formed an independent subclonal lineage, 335 thereby contributing to the ITH. 336
We also assessed the normal cell contamination in both the primary tumor and tumor 337 spheroids using the VAF distribution in each sample. Indeed, both the Primary clone and 338
Ascites clone 1 showed higher VAF distributions than Ascites clone 2, suggesting that the 339 normal-like CNA and SNV profiles in Ascites clone 2 were due to a high proportion of 340 normal cells. These findings are consistent with previous data from ovarian cancer patient-341 15 derived tumor spheroids and mouse models that suggested the presence of tumor-associated 342 macrophages in the center of tumor spheroids [23] . 343
Although we only studied a single high-grade EOC patient, our data support previous 344 studies demonstrating early divergence of the ascites sample from the primary tumor [24] . 345
Further studies are needed to compare similarities and differences between the ascites 346 spheroids and distant metastasis samples. Our data suggest that the mutation set of ascites 347 spheroids does not represent the entire mutational landscape of a given EOC patient. This 348 disagrees with recent findings by Choi et al. [25] showing that ascites tumor cells represent 349 the entire mutational landscape of a given tumor, and no additional genetic aberrations were 350 detected. In contrast, our data showed the presence of genetic heterogeneity within and 351 between the primary tumor and the associated ascites spheroids. Moreover, the primary and 352 associated ascites spheroids diverged early in tumor development, and not all the Primary 353 clones disseminated into the ascites TME. However, our study is limited to a single ascites 354 TME and provided no insight into distant metastatic sites. Our data can partly be explained by the theory of Darwinian selection. For simplicity, 365 tumor evolution is described as a series of expansions of clones, where each expansion series 366 is driven by additional mutation acquisition, and clone fitness is tested by Darwinian 367 selection. This selective sweep is context-dependent, and thus, genetic variants that are 368 beneficial at a certain point may become extinct throughout the period of tumor progression. 369
As a consequence, these clones may be absent in a fully grown tumor [26] . The selective 370 pressures are further influenced by the dynamics of the TME, thereby increasing the 371 complexity of tumor evolution [27] . The presence of extensive ITH in tumor spheroids and 372 the early divergence of these subclones from the primary tumor suggests that we are currently 373 underestimating the tumor genomic landscape. 
Conclusion
386
In this study, we performed genome-wide sequence analysis of the primary tumor 387 and the associated tumor spheroids in the malignant ascites of an EOC patient. We analyzed 388 genetic heterogeneity in the primary tumor and tumor spheroids through multi-region 389 sequencing and the laser-aided cell isolation technique [12] . From the sequencing data, we 390 discovered clonal or subclonal somatic CNAs and SNVs, based on which we constructed 391 17 phylogenetic trees and inferred the evolutionary history of tumor cells in the patient. As a 392 result, we found that the tumor cells in the malignant ascites were an independent lineage 393 from the primary tumor. The phylogenetic analysis showed that the lineage branched before 394 the evolution of the cancer cells at the primary tissues, which suggests that analyzing 395 malignant ascites might be used to detect ovarian cancer or metastasis in the early stage. In 396 summary, the genetic plasticity and similarity between a primary tumor and associated tumor 397 spheroids are still not clear, and yet, the nature of the similarity may have profound 398 implications for both tumor progression and therapeutic outcomes in ovarian cancer. (https://github.com/BiNEL-SNU/PHLI-seq). Isolation of tumor spheroids was performed as 420 described in the prior publication. In brief, an infrared laser was applied to the target area, 421
vaporizing Indium Tin Oxide (ITO) layer and discharging the targeted tumor spheroid on the 422 region. We used glass slides with a 100-nm-thick ITO layer. 423
The 8-strip PCR tube caps for the retrieval of tumor spheroids were pre-exposed under O 2 424 plasma for 2 minutes. The tumor spheroids were lysed using proteinase K (cat no. P4850-425 1ML, Sigma Aldrich) according to the manufacturer's directions after the PCR tubes were 426 centrifuged. For whole-genome amplification, we used GE's Illustra Genomiphi V2 DNA 427 amplification kit (cat no. 25-6600-30). We added 0.2 µl of SYBR green I (Life Technologies) 428 into the reaction solution for real-time monitoring of the amplification (Fig. 2B) . All 429 amplified products were purified using Beckman Coulter's Agencourt AMPure XP kit (cat no. 430 A63880) immediately following the amplification. To prevent carry-over contamination, the 431 pipette tip, PCR tube, and cap for the reaction were stored in a clean bench equipped with UV 432 light and treated with O 2 plasma for 2 minutes before use. Additionally, we monitored the 433 real-time amplification of non-template controls to ensure that no contaminants were 434 transferred. 435
436
Sequencing library preparation, whole-genome, and whole-exome sequencing 437
The whole-genome amplified products or genomic DNA were fragmented using an EpiSonic 438 
